Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition

Area of Science:

• Pediatric Endocrinology
• Neonatal Medicine
• Pharmacology

Background:

• Premature infants, especially those with necrotizing enterocolitis, are susceptible to metabolic complications.
• Hypercalcemia can occur secondary to medical treatments, including furosemide and hydrocortisone infusions.
• Parenteral nutrition management is critical in neonates with gastrointestinal issues.

Observation:

• A 17-day-old premature infant developed hypercalcemia during treatment for necrotizing enterocolitis.
• Initial management involved adjusting calcium in parenteral nutrition, which proved insufficient.
• Pamidronate administration was initiated to address persistent hypercalcemia.

Findings:

• Two doses of pamidronate (3 mg then 2 mg) were administered to the infant.
• Serum calcium levels initially decreased post-pamidronate administration but subsequently normalized.
• The infant tolerated pamidronate without adverse reactions and resumed calcium-containing parenteral nutrition.

Implications:

• Pamidronate may be a viable treatment option for hypercalcemia in neonates.
• Further pediatric clinical trials are essential to establish optimal bisphosphonate dosing and safety profiles.
• Understanding bisphosphonate use in pediatric populations is crucial for managing bone growth and calcium homeostasis.